替奈普酶在大血管闭塞性卒中发病24小时内的疗效:ETERNAL-LVO随机对照试验
ETERNAL-LVO是一项在澳大利亚11个中心开展的3期优效性随机对照试验,纳入发病24小时内、灌注CT显示可挽救组织的大血管闭塞成人患者,比较替奈普酶0.25 mg/kg与标准治疗。主要结局(90天mRS 0-1或恢复至基线)两组无差异(37% vs 43%;调整RR 0.90 [95% CI 0.66-1.21];P=0.48),但研究提前终止使结论无法确定。
要点
- 发病24小时内大血管闭塞且灌注CT存在目标错配的患者,替奈普酶未显著提高90天良好功能结局比例。
- 替奈普酶组症状性颅内出血发生5例(4%),标准治疗组1例(1%)。
- 预设符合方案分析中,转院亚组接受替奈普酶者mRS改善1分的 odds 是标准治疗转院患者的2.61倍(95% CI 1.07-6.40)。
核心结论
- 替奈普酶未增加获得良好功能结局的可能性,但研究提前终止使结论无法确定。
研究设计与样本
- ETERNA-LVO为前瞻性、随机、开放标签、盲法终点、3期优效性试验,在澳大利亚11个初级和综合卒中中心开展。
- 纳入发病24小时内、大血管闭塞且灌注CT显示可挽救组织的成人患者,随机接受替奈普酶0.25 mg/kg或标准治疗。
主要发现
- 主要结局(90天mRS 0-1或恢复至基线)替奈普酶组44例(37%),标准治疗组52例(43%),调整RR 0.90(95% CI 0.66-1.21),P=0.48。
- mRS序贯分析两组无显著差异。
- 预设符合方案分析中,替奈普酶治疗的转院亚组较标准治疗转院患者mRS改善1分的OR为2.61(95% CI 1.07-6.40)。
- 症状性颅内出血替奈普酶组5例(4%),标准治疗组1例(1%)。
临床怎么用
- 对于发病24小时内、大血管闭塞且灌注CT存在目标错配的患者,替奈普酶0.25 mg/kg未显示优于标准治疗的功能结局获益。
- 转院患者亚组的符合方案分析提示替奈普酶可能带来功能改善,但需谨慎解读。
局限性
- 研究因研究药物供应短缺及3期证据出现而提前终止,样本量有限,无法得出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography. METHODS: ETERNAL-LVO (Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion) was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia. The primary outcome was the modified Rankin Scale score of 0 to 1 or return to baseline at 90 days via a modified Poisson regression model. Secondary outcomes include the modified Rankin Scale, considered as an ordinal variable, and symptomatic intracerebral hemorrhage. RESULTS: Following trial initiation, a supply shortage of the investigational product hindered recruitment. When supply resumed, phase 3 evidence had emerged supporting tenecteplase use within 4.5 hours of stroke onset, including large vessel occlusion. ETERNAL-LVO was, therefore, terminated early. Two hundred forty-two participants (median age: 73 years, 43% female, 79% undergoing EVT) were included in the modified intention-to-treat analysis; 120 received tenecteplase and 122 received standard care. No difference in the primary outcome was observed between the tenecteplase (n=44, 37%) and standard care (n=52, 43%; adjusted risk ratio, 0.90 [95% CI, 0.66-1.21]; P=0.48). No significant differences in an ordinal analysis of the modified Rankin Scale were observed between the 2 treatment groups. In a planned per-protocol analysis, the odds of improvement by 1 point in the modified Rankin Scale were doubled in the tenecteplase-treated transfer subgroup compared with standard care transfer patients (odds ratio, 2.61 [95% CI, 1.07-6.40]). Symptomatic intracerebral hemorrhage occurred in 5 (4%) participants assigned to tenecteplase and was present in 1 (1%) participant assigned to standard care. CONCLUSIONS: Treatment with tenecteplase did not increase the likelihood of a favorable functional outcome, but early stoppage of the study prevents definitive conclusions from being drawn. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04454788.
引用
- Yogendrakumar V, Campbell BCV, Churilov L, et al. Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial. Stroke. 2025. PMID: 40927857. doi:10.1161/STROKEAHA.125.052511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。